methyl 3-O-allyl-α-D-galactopyranoside | 129165-06-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: methyl 3-O-allyl-α-D-galactopyranoside
• 英文别名: (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-methoxy-4-prop-2-enoxyoxane-3,5-diol
• CAS: 129165-06-6
• 化学式: C₁₀H₁₈O₆
• 分子量: 234.249
• InChiKey: JUQGZDQHBMDAKB-KGDYZURWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  88.4
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  methyl 3-O-allyl-α-D-galactopyranoside 在 三氟甲磺酸酐 、 二苯基亚砜 、 camphor-10-sulfonic acid 、 2,4,6-三叔丁基嘧啶 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 36.0h， 生成 methyl 3-O-allyl-4,6-O-benzylidene-2-O-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl)-α-D-galactopyranoside
  参考文献：
  名称：

  The synthesis of 2-, 3-, 4- and 6-O-α-d-glucopyranosyl-d-galactopyranose, and their evaluation as nutritional supplements for pre-term infants

  摘要：

  Four methods have been screened for the synthesis of some alpha-D-glucopyrano sides, with the recently reported (Mukaiyama) combination of 2,3,4,6-tetra-O-benzyl- alpha-D-glucopyranosyl iodide and triphenylphosphine oxide being the most successful, especially in the diastereoselectivity exhibited. The alpha-D-glueopyranosides so obtained have been deprotected to yield 2-, 3-, 4- and 6-O-alpha-D-glucopyranosyl-D-galactopyranose. Only the last disaccharide showed any hydrolysis by alpha-glycosidases but this success was not emulated by mucosal extracts from the small intestine of the pig. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.carres.2007.04.022
• 作为产物：
  描述：

  3-溴丙烯 、 Α-D-乳酸吡喃糖苷甲酯 在 四丁基碘化铵 、 二正丁基氧化锡 作用下， 生成 methyl 3-O-allyl-α-D-galactopyranoside
  参考文献：
  名称：

  合成粘蛋白片段：甲基3-O-（2-乙酰氨基-2-脱氧-β-d-吡喃葡萄糖基）-β-d-吡喃半乳糖苷和甲基3-O-（2-乙酰氨基-2-脱氧-3-O-β -d-半乳糖吡喃糖基-β-d-吡喃葡萄糖基）-β-d-吡喃半乳糖苷

  摘要：

  摘要甲基2,4,6-三-O-苄基-β-d-吡喃半乳糖苷（5）是通过其3-O-烯丙基衍生物获得结晶的，该衍生物又通过假定3的开环获得，甲基β-d-吡喃半乳糖苷的4-O-亚锡基衍生物，然后进行苄基化。5与2-甲基-（2-乙酰氨基-3,4,6-三-O-乙酰基-1,2-二脱氧-β-d-吡喃吡喃）-[2,1-d] -2-恶唑啉的缩合反应在对甲苯磺酸存在下的1，2-二氯乙烷得到二糖衍生物甲基3-O-（2-乙酰氨基-3,4,6-三-O-乙酰基-2-脱氧-β-d-吡喃葡萄糖基）- 2,4,6-三-O-苄基-β-d-吡喃半乳糖苷（6）。在甲醇甲醇钠中将6脱乙酰化，得到二糖衍生物7，将其与α，α-二甲氧基甲苯缩醛化，得到4'，6'-O-亚苄基乙缩醛（10）。7的苄基的催化氢解得到标题二糖8。在氰化汞的存在下，在1：1苯硝基甲烷中，用2,3,4,6-四-O-乙酰基-α-d-吡喃半乳糖基溴化物进行10的糖基化，得

  DOI：

  10.1016/0008-6215(84)85070-3

文献信息

• Regioselective mono and multiple alkylation of diols and polyols catalyzed by organotin and its applications on the synthesis of value-added carbohydrate intermediates
  作者：Hengfu Xu、Bo Ren、Wei Zhao、Xiaoting Xin、Yuchao Lu、Yuxin Pei、Hai Dong、Zhichao Pei

  DOI：10.1016/j.tet.2016.04.076

  日期：2016.6

  A catalytic amount of dibutyltin dichloride was used to develop regioselective alkylation of diols and multiple alkylation of polyols. Alkyl groups, including allyl, alkynyl and long-chain alkyl groups, were successfully introduced to one or two hydroxyl groups of carbohydrate and nonsugar substrates. In most cases, excellent isolation yields were obtained. The alkynylated carbohydrates may be used

  催化量的二氯化二丁基锡用于发展二醇的区域选择性烷基化和多元醇的多重烷基化。包括烯丙基，炔基和长链烷基在内的烷基已成功引入到碳水化合物和非糖底物的一个或两个羟基上。在大多数情况下，可获得优异的分离产率。炔化的碳水化合物可用于通过点击反应以高效率合成寡糖模拟物。具有长链烷基的碳水化合物可用作表面活性剂，本研究中的实验进一步证明了这一点。
• [EN] NOVEL GALACTOSIDE INHIBITOR OF GALECTINS<br/>[FR] NOUVEL INHIBITEUR DE GALECTINES DU TYPE GALACTOSIDE
  申请人：GALECTO BIOTECH AB

  公开号：WO2021001538A1

  公开（公告）日：2021-01-07

  The present invention relates to a D-galactopyranose compound of formula (1) wherein the pyranose ring is α-D-galactopyranose, and these compounds are high affinity galectin-3 inhibitors for use in treatment of inflammation; Inflammation induced thrombosis; Atopic dermatitis; Acute coronary syndrome; fibrosis, such as pulmonary fibrosis, liver fibrosis, kidney fibrosis, ophthalmological fibrosis and fibrosis of the skin and heart; local fibrosis such as Dupuytren's disease and Peyronie's disease; fibrotic complications of other therapies such as coronary stents, bile duct stents, cerebral artery stents, ureter stents; scleroderma; scarring; keloid formation; covid-19; acute lung injury; ARDS; viral pneumonitis, aberrant scar formation; surgical adhesions; septic shock; cancer, such as colorectal cancer, other gastrointestinal carcinomas such as pancreatic cancer, gastric cancer, biliary tract cancer, lung cancers, mesothelioma, female cancers like breast cancer, ovarian cancer, uterine cancer, cancer of the cervix uteri, cancer of the salpingx, cerebral cancers such as medulloblastomao, glioma, meningioma, sarcomas of the bones and muscles and other sarcomas, leukemias and lymphomas, such as T-cell lymphomas; transplant rejection; metastasising cancers; ageing; Dementia; Alzheimers; TGFbeta driven bone disease such as osteogenesis imperfecta; Pulmonary hypertension; autoimmune diseases, such as psoriasis, rheumatoid arthritis, Rheumatoid lung; Crohn's disease, ulcerative colitis, ankylosing spondylitis, systemic lupus erythematosus; viral infections such as influenza virus, HIV, Herpes virus, Coronaviruses, Hepatitis C; metabolic disorders; heart disease; heart failure; pathological angiogenesis, such as ocular angiogenesis or a disease or condition associated with ocular angiogenesis, e.g. neovascularization related to cancer; and eye diseases, such as age-related macular degeneration and corneal neovascularization; atherosclerosis; metabolic diseases; diabetes; type I diabetes; type 2 diabetes; insulin resistens; obesity; Marfans syndrome; Loeys–Dietz syndrome; nephropathy; Diastolic HF; fibrotic lung complications of aPD1 and other CPI therapies; asthma and other interstitial lung diseases, including Hermansky-Pudlak syndrome, liver disorders, such as non- alcoholic steatohepatitis or non-alcoholic fatty liver disease; uterine disease such as uterine fibroids and uterine or cervical fibrosis.

  本发明涉及一种化学式（1）中的D-半乳糖吡喃糖类化合物，其中吡喃糖环为α-D-半乳糖吡喃糖，这些化合物是高亲和力的galectin-3抑制剂，用于治疗炎症；炎症诱导性血栓形成；特应性皮炎；急性冠状动脉综合征；纤维化，如肺纤维化、肝脏纤维化、肾脏纤维化、眼科纤维化和皮肤和心脏的纤维化；局部纤维化，如杜普伊特伦氏病和佩罗尼氏病；其他治疗的纤维化并发症，如冠状支架、胆管支架、脑动脉支架、输尿管支架；硬皮病；瘢痕形成；瘢痕增生；新冠肺炎；急性肺损伤；ARDS；病毒性肺炎；异常瘢痕形成；手术粘连；脓毒性休克；癌症，如结直肠癌、其他胃肠道癌症如胰腺癌、胃癌、胆道癌、肺癌、间皮瘤、女性癌症如乳腺癌、卵巢癌、子宫癌、宫颈癌、输卵管癌、脑癌如髓母细胞瘤、胶质瘤、脑膜瘤、骨骼和肌肉的肉瘤和其他肉瘤、白血病和淋巴瘤，如T细胞淋巴瘤；移植排斥；转移性癌症；衰老；痴呆症；阿尔茨海默病；TGFbeta驱动的骨疾病，如骨发育不全；肺动脉高压；自身免疫疾病，如牛皮癣、类风湿关节炎、类风湿肺；克罗恩病、溃疡性结肠炎、强直性脊柱炎、系统性红斑狼疮；病毒感染，如流感病毒、HIV、疱疹病毒、冠状病毒、丙型肝炎；代谢紊乱；心脏病；心力衰竭；病理性血管生成，如眼部血管生成或与眼部血管生成相关的疾病或症状，例如与癌症相关的新血管生成；眼部疾病，如老年性黄斑变性和角膜新血管生成；动脉粥样硬化；代谢性疾病；糖尿病；1型糖尿病；2型糖尿病；胰岛素抵抗；肥胖；马凡氏综合征；洛伊斯-迪茨综合征；肾病；舒张期心力衰竭；PD1和其他CPI疗法的肺纤维化并发症；哮喘和其他间质性肺疾病，包括赫尔曼斯基-普德拉克综合征、肝脏疾病，如非酒精性脂肪性肝炎或非酒精性脂肪肝病；子宫疾病，如子宫肌瘤和子宫或宫颈纤维化。
• Stereoselectivity in Glycosylation with Deoxofluorinated Glucosazide and Galactosazide Thiodonors
  作者：Martin Kurfiřt、Lucie Červenková Št’astná、Martin Dračínský、Monika Müllerová、Vojtěch Hamala、Petra Cuřínová、Jindřich Karban

  DOI：10.1021/acs.joc.9b00705

  日期：2019.5.17

  stereoselectivity in glycosylation with deoxofluorinated glycosyl donors is critical for assembly of fluorinated oligosaccharides. Here, we report the synthesis of benzylated 3-fluoro and 4-fluoro analogues of phenyl 1-thioglucosazide and galactosazide donors and evaluation of their stereoselectivity in glycosylation of a series of model carbohydrate acceptors using the Tf2O/Ph2SO promoter system. Low-temperature

  用脱氧氟化的糖基供体控制糖基化中的端基立体选择性对于组装氟化寡糖至关重要。在这里，我们报告了苯基1-硫代葡萄糖叠氮化物和半乳糖叠氮化物供体的苄基化3-氟和4-氟类似物的合成，以及使用Tf 2 O / Ph 2 SO启动子系统评估了一系列模型糖受体的糖基化中的立体选择性。低温NMR显示在选择的糖基化条件下形成共价α-三氟甲磺酸酯和氧代tri三氟甲磺酸酯的两种异构体。这项研究证明了立体选择性如何取决于受体反应性和糖基供体构型。反应性受体有利于两个d均形成1，2-反式-β-糖苷-葡糖和d -半乳糖供体，而反应性差的受体有利于形成1,2-顺-α-苷与d -半乳糖供体但非选择性的与d -葡萄糖供体。
• Synthesis and conformation of 2,6-dioxabicyclo[3.1.1]heptanes: 1,3-anhydro-2,4,6-tri-O-benzyl-β-d-galactopyranose
  作者：Fanzuo Kong、Depei Lu、Shuhua Zhou

  DOI：10.1016/0008-6215(90)84284-2

  日期：1990.4
• Synthesis of the Tetrasaccharide Repeating Unit of the Antigen from <i>Escherichia coli</i> O126 as Its Methyl Glycoside
  作者：Anup Kumar Misra、Nirmolendu Roy

  DOI：10.1080/07328309808001883

  日期：1998.9.1

  The tetrasaccharide repeating unit (17) of the antigen from E, coli O126 has been synthesized as its methyl glycoside by sequential addition of monosaccharide derivatives. The formation of the beta-mannosidic linkage was achieved by Swern oxidation of the glucose derivative followed by reduction of the product with sodium borohydride.